Emmanuel Lacroix is Vice President and Partner at UCB Ventures, an early-stage corporate venture fund.
Dr. Lacroix has a particular interest in biotech start-ups that leverage novel biology or technology platforms to develop breakthrough therapeutics, especially in diseases associated with impaired cell and tissue homeostatis and/or progressive degeneration.
Previously, Dr. Lacroix served as UCB’s Head of Business Development Neurology where he led the execution of multiple partnership and license agreements, product acquisitions, and other investments. Dr. Lacroix held prior leadership positions in Sales and Global Marketing, at UCB, and in Discovery Research for Gene Editing at Cellectis SA.
Dr. Lacroix currently also serves on the Boards of Syndesi Therapeutics, a UCB spinout company, and Locanabio (as observer), a company pioneering novel gene therapies targeting RNA. He held a prior Board observer position with Lumos Pharma, a rare disease company now traded on Nasdaq. Dr. Lacroix received an MBA from IMD (Switzerland), a Ph.D. in Molecular Biology from ULB (Belgium) based on protein engineering research conducted at the European Molecular Biology Laboratory (Germany), and a MSc in Biochemistry from the ULG (Belgium).